Design, synthesis and biological evaluation of novel indole-3-carboxylic acid derivatives with antihypertensive activity

Bioorg Med Chem Lett. 2023 Jun 15:90:129349. doi: 10.1016/j.bmcl.2023.129349. Epub 2023 May 25.

Abstract

Molecular design, synthesis, in vitro and in vivo studies of novel derivatives of indole-3-carboxylic acid new series of angiotensin II receptor 1 antagonists is presented. Radioligand binding studies using [125I]-angiotensin II displayed that new derivatives of indole-3-carboxylic acid have a high nanomolar affinity for the angiotensin II receptor (AT1 subtype) on a par with the known pharmaceuticals such as losartan. Biological studies of synthesized compounds in spontaneously hypertensive rats have demonstrated that compounds can lower blood pressure when administered orally. Maximum the decrease in blood pressure was 48 mm Hg with oral administration of 10 mg/kg and antihypertensive effect was observed for 24 h, which is superior to losartan.

Keywords: Angiotensin II receptor 1 antagonist; Antihypertension drug; Hypertension; Indole-3-carboxylic acid.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin II / pharmacology
  • Angiotensin Receptor Antagonists / chemistry
  • Angiotensin Receptor Antagonists / pharmacology
  • Animals
  • Antihypertensive Agents* / pharmacology
  • Antihypertensive Agents* / therapeutic use
  • Biphenyl Compounds / chemistry
  • Blood Pressure
  • Hypertension* / drug therapy
  • Losartan / pharmacology
  • Rats
  • Rats, Inbred SHR
  • Receptors, Angiotensin / metabolism
  • Tetrazoles / chemistry

Substances

  • Antihypertensive Agents
  • Losartan
  • indole-3-carboxylic acid
  • Angiotensin Receptor Antagonists
  • Receptors, Angiotensin
  • Angiotensin II
  • Tetrazoles
  • Biphenyl Compounds